Literature DB >> 16080195

Analysis of Aurora-A and hMPS1 mitotic kinases in mantle cell lymphoma.

Emma Camacho1, Silvia Beà, Itziar Salaverría, Armando López-Guillermo, Xavier Puig, Yolanda Benavente, Silvia de Sanjosé, Elias Campo, Luis Hernández.   

Abstract

Aurora-A and hMPS1 are kinases involved in spindle checkpoint and centrosome duplication regulation and whose alterations have been associated with cell transformation and chromosome instability in different tumor models. In this study, we have examined the possible alterations of these genes in 58 mantle cell lymphomas (MCLs) and 4 MCL-related cell lines. Aurora-A was also examined in 46 diffuse large B-cell lymphomas (DLBCLs). Aurora-A and hMPS1 mRNA expression levels were related to tumor proliferative activity. Interestingly, a MCL case with the highest number or chromosomal imbalances also showed an extremely high value of Aurora-A mRNA expression. No Aurora-A gene amplifications were detected in any tumor or cell line, whereas hemizygous hMPS1 gene deletions were observed in 23% of MCLs and 3 of the 4 cell lines. However, no expression alterations or gene mutations were detected in these cases. The Aurora-A proposed cancer susceptibility polymorphic variant (P31I) was observed with a similar frequency in MCL, DLBCL, chronic lymphocytic leukemia and in the 431 healthy controls. However, the 3 MCLs and 4 DLBCLs with the homozygous variant of this polymorphism had particular clinical characteristics with an unusual early-age presentation and second epithelial malignancies in MCL and extranodal origin in DLBCL. These findings indicate that Aurora-A and hMPS1 aberrations are uncommon in aggressive lymphomas but Aurora-A overexpression may contribute to numerical chromosomal alterations in occasional MCL. Although the Aurora-A P31I polymorphic variant is not directly involved in a genetic predisposition to these lymphomas, it may modulate the clinical presentation of these tumors. Copyright 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16080195     DOI: 10.1002/ijc.21370

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  11 in total

1.  Aurora A inhibitor (MLN8237) plus vincristine plus rituximab is synthetic lethal and a potential curative therapy in aggressive B-cell non-Hodgkin lymphoma.

Authors:  Daruka Mahadevan; Amy Stejskal; Laurence S Cooke; Ann Manziello; Carla Morales; Daniel O Persky; Richard I Fisher; Thomas P Miller; Wenqing Qi
Journal:  Clin Cancer Res       Date:  2012-02-28       Impact factor: 12.531

2.  Aurora A Kinase Inhibition Selectively Synergizes with Histone Deacetylase Inhibitor through Cytokinesis Failure in T-cell Lymphoma.

Authors:  Kelly M Zullo; Yige Guo; Laurence Cooke; Xavier Jirau-Serrano; Michael Mangone; Luigi Scotto; Jennifer E Amengual; Yinghui Mao; Renu Nandakumar; Serge Cremers; Jimmy Duong; Daruka Mahadevan; Owen A O'Connor
Journal:  Clin Cancer Res       Date:  2015-04-15       Impact factor: 12.531

3.  Disruption of Aneuploidy and Senescence Induced by Aurora Inhibition Promotes Intrinsic Apoptosis in Double Hit or Double Expressor Diffuse Large B-cell Lymphomas.

Authors:  Shariful Islam; Wenqing Qi; Carla Morales; Laurence Cooke; Catherine Spier; Eric Weterings; Daruka Mahadevan
Journal:  Mol Cancer Ther       Date:  2017-06-14       Impact factor: 6.261

Review 4.  The potential role of Aurora kinase inhibitors in haematological malignancies.

Authors:  Sherif S Farag
Journal:  Br J Haematol       Date:  2011-10-08       Impact factor: 6.998

5.  Aurora inhibitor MLN8237 in combination with docetaxel enhances apoptosis and anti-tumor activity in mantle cell lymphoma.

Authors:  Wenqing Qi; Laurence S Cooke; Xiaobing Liu; Lisa Rimsza; Denise J Roe; Ann Manziolli; Daniel O Persky; Thomas P Miller; Daruka Mahadevan
Journal:  Biochem Pharmacol       Date:  2011-02-01       Impact factor: 5.858

6.  Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas.

Authors:  Jonathan W Friedberg; Daruka Mahadevan; Erin Cebula; Daniel Persky; Izidore Lossos; Amit B Agarwal; Jungah Jung; Richard Burack; Xiaofei Zhou; E Jane Leonard; Howard Fingert; Hadi Danaee; Steven H Bernstein
Journal:  J Clin Oncol       Date:  2013-09-16       Impact factor: 44.544

Review 7.  Cell Cycle Dysregulation in Mantle Cell Lymphoma: Genomics and Therapy.

Authors:  Kevin Wang; Xiangao Huang; Maurizio Di Liberto; Selina Chen-Kiang
Journal:  Hematol Oncol Clin North Am       Date:  2020-08-01       Impact factor: 3.722

8.  Phase 1 study of alisertib (MLN8237) and weekly irinotecan in adults with advanced solid tumors.

Authors:  Thomas J Semrad; Edward J Kim; I-Yeh Gong; Tianhong Li; Scott Christensen; Mili Arora; Jonathan W Riess; David R Gandara; Karen Kelly
Journal:  Cancer Chemother Pharmacol       Date:  2021-05-15       Impact factor: 3.288

Review 9.  Action mechanisms of histone deacetylase inhibitors in the treatment of hematological malignancies.

Authors:  Yoichi Imai; Yoshiro Maru; Junji Tanaka
Journal:  Cancer Sci       Date:  2016-11-04       Impact factor: 6.716

Review 10.  Scientific Rationale Supporting the Clinical Development Strategy for the Investigational Aurora A Kinase Inhibitor Alisertib in Cancer.

Authors:  Huifeng Niu; Mark Manfredi; Jeffrey A Ecsedy
Journal:  Front Oncol       Date:  2015-08-24       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.